TG Therapeutics, Inc. (TGTX)
NCM · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 141.1M | 161.7M | 192.6M | 204.9M |
| Gross Profit | 122.2M | 133.6M | 154.4M | 171.4M |
| Operating Income | 34.8M | 29.4M | 50.5M | 34.8M |
| Net Income | 28.2M | 390.9M | 23.0M | 19.8M |
| Diluted EPS | $0.17 | $2.43 | $0.14 | $0.12 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 2.8M | 233.7M | 329.0M | 616.3M |
| Gross Profit | 2.5M | 219.5M | 290.5M | 515.6M |
| Operating Income | -218.3M | 20.6M | 41.9M | 123.3M |
| Net Income | -223.8M | 12.7M | 23.4M | 447.2M |
| Diluted EPS | $-1.46 | $0.09 | $0.15 | $2.77 |